名臣健康(002919) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥320,049,119.74, a decrease of 30.22% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2024 was ¥36,415,158.14, down 45.02% year-on-year[3]. - The net profit after deducting non-recurring gains and losses for Q3 2024 was ¥37,315,384.77, a decrease of 41.86% compared to the previous year[3]. - Total operating revenue for the third quarter was ¥984,704,973.19, a decrease of 24.5% from ¥1,303,240,197.69 in the previous year[15]. - Net profit for the third quarter was ¥96,790,316.11, a decline of 41.7% compared to ¥165,872,454.96 in the same period last year[16]. - Earnings per share for the third quarter were ¥0.36, down from ¥0.62 in the previous year[16]. Assets and Liabilities - The total assets as of September 30, 2024, were ¥1,202,796,623.22, reflecting a decline of 5.59% from the end of the previous year[3]. - Total assets decreased from 1,274,031,659.57 CNY to 1,202,796,623.22 CNY, a decline of approximately 5.6%[12]. - The total liabilities decreased to ¥329,387,018.11 from ¥464,145,362.32, reflecting a reduction of 29.0%[15]. - The total equity attributable to shareholders increased to ¥873,397,373.38 from ¥809,886,297.25, an increase of 7.8%[15]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥56,678,574.83, an increase of 504.16% compared to the same period last year[8]. - Operating cash inflow for Q3 2024 was CNY 922,951,805.76, a decrease of 17.0% from CNY 1,112,457,313.85 in Q3 2023[17]. - Operating cash outflow for Q3 2024 was CNY 866,273,230.93, down from CNY 1,126,481,044.05 in Q3 2023, resulting in a net cash flow from operating activities of CNY 56,678,574.83 compared to a loss of CNY 14,023,730.20 in the previous year[17]. - The net increase in cash and cash equivalents for Q3 2024 was -CNY 35,059,470.79, an improvement from -CNY 39,431,648.17 in Q3 2023[18]. - The ending balance of cash and cash equivalents for Q3 2024 was CNY 131,421,998.45, up from CNY 96,501,752.44 in Q3 2023[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,315[9]. - The largest shareholder, Chen Qinfang, holds 35.02% of the shares, totaling 93,338,604 shares[10]. - The largest shareholder, Chen Qinfang, has pledged 9,144,000 shares[9]. - The company has not reported any significant changes in the top 10 shareholders' participation in margin trading[10]. Operational Expenses - Research and development expenses were ¥48,895,920.66, a decrease of 44.3% from ¥87,666,455.91 year-over-year[15]. - Sales expenses decreased to ¥346,351,879.32, down 30.2% from ¥496,690,001.13 in the previous year[15]. Investment Activities - The company reported a significant increase in investment income of 392.83%, amounting to ¥146,789.23, primarily due to increased returns from financial products[7]. - The net cash flow from investing activities was negative at ¥42,184,341.72, a significant decrease of 722.96% compared to the previous year, mainly due to the purchase of financial products[8]. - Investment cash inflow for Q3 2024 was CNY 149,815,082.81, significantly higher than CNY 39,031,189.28 in Q3 2023[17]. - Investment cash outflow for Q3 2024 totaled CNY 191,999,424.53, compared to CNY 44,157,122.23 in Q3 2023, leading to a net cash flow from investing activities of -CNY 42,184,341.72, worsening from -CNY 5,125,932.95 in the previous year[17].